Dr. Sonny Schelin has been central to the further development of thermotherapy treatment in benign prostate enlargement to what it is today. He is also the brains and co-inventor behind CoreFlow, an innovation with multiple functions.
Schelin has contributed to many other things in urology; Schelin was, among other things, the one who initiated triple treatment in prostate cancer in the mid-1990s and where long-term follow-up now shows that this initiative reduced prostate cancer-specific mortality compared to the previous standard treatment.
The study was published in the Scandinavian Journal of Urology in April 2019: https://bit.ly/34JolmB
Schelin currently works at the Specialist Medical Group in Kalmar, which primarily handles benign urological conditions. There he cures, among other things, together with his co-workers, BPE patients from all over the country. There, ProstaLund’s thermotherapy treatment with CoreTherm is an important part of the business.
ProstaLund AB (publ) is a Swedish medical technology company headquartered in Lund that develops and markets innovative products for the treatment of benign prostate enlargement. The company has patented the treatment method CoreTherm, an individualized thermotherapy treatment for BPE (benign prostatic enlargement). In October 2020, the company launched CoreFlow – Soft stent in Sweden.
ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,300 shareholders. See also – www.prostalund.se.